Aneta Gawlik


The ESPE Research Unit Grant is a collaborative research grant which aims to foster, facilitate, coordinate, and identify topics for high quality research in paediatric endocrinology, for both physicians and scientists.


Grant information

  • The ESPE Research Unit is open to ESPE members who intend to support collaborative research among members. Grant applications must have a designated principal investigator and at least two co-investigators who are ESPE members. Non-ESPE members may participate as additional co-investigators. Applications that consist of applicants from at least three different countries are strongly encouraged.
  • One large grant will be awarded. The grant of €100,000 is for a period of two years (up to €50,000 per year).
  • The grant covers salary, materials and consumables, small items of equipment, collaborative visits and overheads that should be less than 10% of the total value.

Eligibility criteria

Specific requirements

  • The principal investigator and at least two co-investigators MUST be ESPE members in order for the application to be applicable. Non-ESPE members may participate as additional co-investigators. If you are not a member then apply here.
  • Majority of the research should be performed at the investigators’ centre.
  • Beneficiaries of the Research Unit Grant may not hold more than one Research Unit Grant at any one time. This does not apply to non-beneficiaries. 
  • Current members of the Science Committee and ESPE Council are not eligible to apply for this grant as a co-investigator who is a financial beneficiary of the grant.
  • Applications from candidates who are based in the same research group as any member of the Science Committee cannot be considered for the grant, i.e. members of the Science Committee cannot be involved in the development, execution or outcomes of the project, including any publications resulting from the grant to upcoming projects and activities, nor in the decision on the grant allocation.
  • ESPE Research Unit awards can only be submitted by ESPE members who intend to support collaborative research among members.
  • Grant holders will be asked to present the status of their research at the Annual ESPE meeting, one year after completion of the grant.
  • A grant must be activated within 6 months of receipt by submitting a grant payment form.
  • No Principal Investigator can hold two Research Unit Grants at any one time. If they wish to apply again they must have completely finished their previous project. Principal Investigators can however be supporting investigators in new applications whilst they hold a grant as PI. Applications will be selected on merit as per usual.
  • NOTE: ESPE is not currently accepting applications from Russia or Belarus.

Selection criteria

Applications will be scored based on the following criteria:

  • Applicant CV
  • Host CV and institution (if applicable)
  • Focus and quality of application
  • Hypothesis
  • Methodology and experimental design
  • Potential for publication and further research
  • Timing and feasibility
  • Budget justification
  • Benefit for applicant and home institution
  • Relevance of the topic for the field of paediatric endocrinology

If you have any queries regarding the scientific content of your application, please contact the Research Unit convenor Professor Aneta Gawlik for discussion. Any queries regarding documentation administration, both in the application stage and in the grant claim stage, should be directed to the ESPE Office.


The application and evaluation procedures take place in two stages:

  • All preliminary applications will be assessed for eligibility by the ESPE Research Unit Convenor.
  • All applications that fulfill the criteria of the grant will be invited to submit a final application.
  • All final applications will be subjected to a peer review by at least three experts in the field  that will include Science Committee Expert Panel and external reviewers.
  • The ESPE Research Unit Convenor will select the external expert reviewers from the scientific community. 
  • Ranking is made by each reviewer independently based on the named selection criteria. The highest ranked projects are granted the award after approval by the ESPE Science Committee. The reviewer evaluation form is used in this process.
  • The ESPE Science Committee reserves the rights to withhold the award if the applications are deemed poor in quality.

Post Award information and form submission guidelines

The forms below are for recipients of this grant only. The grant is paid in two annual instalments. The initial grant payment form must indicate the start date of the project, and the first payment  will be scheduled for 1 month before this date. Please submit all receipts/invoices/bills related to payments being claimed with the forms. Please note that any publications resulting from the research should contain the following sentence: “This research was made possible through a Research Unit Grant, sponsored by the European Society of Paediatric Endocrinology – ESPE”.
Papers published in connection with this research and any manuscripts in press should be submitted with the Final Report.

  • Grant Payment Form – Should be submitted within six months of being awarded the grant before beginning the project and then each time a payment is being requested (every 12 months – two required in total).
  • Grant Accountability Report – Should be submitted after the first 12 months, and within three months of completion of the grant (two required in total).
  • Grant Report Form – Should be submitted 12 months into the grant and within three months of completion of the grant (two required in total).

All forms must be submitted to the ESPE Team


The ESPE Research Unit Grant is supported by ESPE.

Grant winners

2021-2023 | Humanin, a novel target to improve bone health in chronic inflammation

Lars Sävendahl (Sweden), Colin Farquharson (United Kingdom), Jarod Wong (United Kingdom), Farasat Zaman (Sweden), Claes Ohlsson (Sweden), Ondrej Soucek (Czech Republic)

2020-2022 | Clinical, genetic and molecular characteristics of childhood-onset osteoporosis

Outi Mäkitie (Sweden), Nick Shaw (United Kingdom), Corinna Grasemann (Germany), Serap Turan (Turkey)

2019-2021 | New clinical and molecular findings in patients with inactivating PTH/PTHrP signalling disorders (iPPSDs)

Guiomar Perez de Nanclares (Spain), Luisa De Sanctis (Italy), Francesca Marta Elli (Italy), Agnès Linglart (France), Anne Guiochon-Mantel (France), Giovanna Mantovani (Italy), Isolina Riaño (Spain)

2019-2020 | ViD-MeX – Pilot study on Vitamin D metabolism in X-linked hypophosphatemic rickets (XLH)

Adalbert Raimann (Austria), Agnès Linglart (France), Dirk Schnabel (Germany), Tomaz Rozmaric (Austria)

2018-2020 | Silver Russell Syndrome and metabolic function: building the knowledge for transition and care into adulthood

Irene Netchine (France), Mohamad Maghnie (Italy), Justin Davies (United Kingdom), Jovanna Dahlgren (Sweden), Susan O’Connell (Ireland), Anita Hokken Koelega (Netherlands), Gerhard Binder (Germany)

2018-2019 | Potential of humanin to prevent bone growth impairment and osteoporosis in IBD

Lars Savendahl (Sweden), Colin Farquharson (United Kingdom), Ondrej Soucek (Czech Republic), Jarod Wong (United Kingdom)

2017-2019 | Personalized approach to non-syndromic childhood obesity using multi-omics disease signature

Aneta Gawlik (Poland), Ze’ev Hochberg (Israel), Stefan A. Wudy (Germany), Michael Shmoish (Israel), Malgorzata Wasniewska (Italy), Abdullah Bereket (Turkey)

2017-2019 | Comparison of the short and medium term side effects of first bisphosphonate infusion between children with different underlying bone pathologies

Moira Cheung (United Kingdom), Wolfgang Högler (United Kingdom), Oliver Semler (Germany), Adalbert Raimann (Austria) 

2016-2018 | Improvement of Diagnostic workup for congenital hypothyroidism by a multigene NGS panel: A multicenter study to compare diagnostic accuracy and cost effectiveness

Gabor Szinnai, Johnny Deladoëy, Michel Polak, Heiko Krude, Paul van Trotsenburg (Switzerland, Canada, France, Germany, Netherlands)

2016-2018 | Identification of novel genetic causes of familial central precocious puberty

Magdalena Stefanija Avbel, Liat de Vries, Taneli Raivio (Slovenia, Israel, Finland)

2016-2018 | YESS! Introduction of the Young Endocrine Support System in the transition from paediatric to adult endocrine care

Laura de Graaff, Sabine Elisabeth Hannema, Martine Cools, Gary Butler, Jesus Argente (Netherlands, Belgium, United Kingdom, Spain)

2015-2016 | In search for novel monitoring tools to detect chronic over- or under-treatment in children with CAH

E van den Akker, E. Charmandari, C. Flueck (Netherlands, Greece, Switzerland)

2014-2016 | Cellular Modelling of Human Gonad Sex-Determination

Anu Bashamboo, Ken McElreavey, Raja Brauner, Andy Greenfield, Radha Saraswathy, Faisal Ahmed (France, United Kingdom, India)

2014-2016 | Managing clitoromegaly in childhood in girls with CAH: an investigation of the psychological impact of current treatment strategies

Elisabeth Crowne, Julie Alderson, Naomi Crouch, Faisal Ahmed (United Kingdom)

2014-2015 | What is the dose response of varying meal content of fat on postprandial glycaemia in children with T1DM?

Susan M O’Connell, Amir Shafat, Bruce King (Ireland, Australia)

2012-2014 | Understanding the molecular basis of diabetes mellitus associated with novel syndromes

K Hussain, K Raile, F Darendeliler (United Kingdom, Germany, Turkey)

2012-2014 | The impact of obesity on the molecular mechanisms involved in the development of metabolic abnormalities in children and adolescents

B Spiliotis, W Kiess, J Argente (Greece, Germany, Spain)

2011-2012 | New Genes for Neonatal Diabetes (ND) and Hyperinsulinemic Hypoglycemia (HH)

F Barbetti, RW Holl, CG Nichols (Italy, Germany, USA)

2011-2012 | Study of early endocrine profile in infants with Prader-Willi syndrome (PWS) in order to unravel the switch from early feeding difficulties to obesity and hyperphagia

M Tauber, A Hokken–Koelaga, B Hauffa, A Goldstone V Beauloye, R Nergardh (France, Netherlands, Germany, United Kingdom, Belgium, Sweden)

2011-2012 | Abnormal Thyroid Development: a Model Disorder for Congenital Malformations and Neurocognitive Development

J Deladoey, M Polak, S Costagliola, G Van Vliet (Canada, France, Belgium)

2011-2012 | EuroPHPnet, a unique tool to decipher the Gsa dependent signalling pathways

A Linglart, C Silve, O Hiort, S Thiele, S Fischer, L De Sanctis, A Spada, G Perez De Nanclares, K Freson (France, Germany, Italy, Spain, Belgium)

2010-2012 | Infant manifestations of adult obesity susceptibility genotypes

K. Ong, B. Heude, L. Ibáñez, D. Dunger, MA Charles, F. de Zegher (United Kingdom, France, Spain, Belgium)

2009-2011 | Effects of endocrine disrupting chemicals (EDC) on GnRH neuronal function

S Heger, A–S Parent, V Prevot (Germany, Belgium, France)

2009-2011 | Congenital Hyperinsulinism: Genes, phenotype and treatment

HB Christesen, V Peterkova, AN AlMutair, K Brusgaard (Denmark, Russia, Saudi Arabia)

2008-2010 | Anti–Müllerian hormone levels in girls with Turner’s syndrome: A possible predictor of ovarian function

CE Flück, JA Visser, MB Ranke, A Hokken-Koelege (Switzerland, Netherlands, Germany)

2008-2009 | Safety and Appropriateness of Growth Hormone treatments in Europe (SAGHE)

JC Carel, S Cianfarani, G Butler, L Savendahl (France, Italy, United Kingdom, Sweden)

2008-2009 | Endocrine and Genetic Characteristics of the Pygmy Population in South Western Uganda

Z Hochberg, E Mworozi, C Camacho-Hübner, M. Dattani (Israel, Uganda, Sweden, United Kingdom)

2007-2009 | Molecular regulation of normal thyroid development and function and their diseases

M Polak, G. Szinnai, J. Moreno (France, Switzerland, Netherlands)

2007-2009 | Investigation of mitochondrial function and alterations in the mitochondrial proteome during development of obesity

AN Eberle, P Liniger, IM Fearnley, JE Walker, R Peterli, T Peters, U Zumsteg, J Mayr (Switzerland, United Kingdom)

2007-2008 | Identification of ABCC8 mutations in atypical type 1 diabetes patients and possible treatment consequencesy

PR Njølstad, A Molven, HB Mortensen, L Castaño (Norway, Denmark, Spain)

2006-2008 | Exploring the utility of a European register of disorders of sex development / DSD

SF Ahmed, O Hiort, S Bertelloni, IA Hughes, SLS Drop, K Robertson (United Kingdom, Germany, Italy, Netherlands)

2005-2007 | Molecular regulation of the growth plate

J M Wit, L Sävendahl, G Rappold (Netherlands, Sweden and Germany)

2005-2006 | Networking in Paediatric Endocrine Disruptors

J Toppari, J Anders, O Söder, JP Bourguignon, I Hughes, C Acerini, C Sultan (Finland, Denmark, Sweden, Belgium, United Kingdom, France)

2004-2006 | Screening and characterisation of DAX1–Interacting Proteins

A Tiulpakov, P Rubtson, W Sippell, N Krone, J Achermann (Russian Federation, Germany, United Kingdom)

2004-2005 | Effects ACE-inhibitors on endothelial dysfunction and markers of angiopathy and oxidative stress in adolescent and young adults with type 1 diabetes

Angelika Mohn, M Vanelli, T Danne, H. Mortensen (Italy, Germany, Denmark)

2003-2005 | Rickets in Children of Middle Eastern Origin

G Saggesse, G Baroncelli, L Audi, A Bereket, H Delemarre–van de Waal, M El Kholy, Z Hochberg, E Schonau, N Shaw (Italy, Spain, Turkey, Netherlands, Egypt, Israel, Germany, United Kingdom)

2002 | The role of the Ihh/PTHrP feedback loop in the human growth plate: A concerted European action

L Sävendahl. JM Wit, H Robson, GR Williams, P Moshe, I Hughes, T Siebler, M Corvol, S van Buul-Offers (Sweden, The Netherlands, United Kingdom, Israel, Germany)

2001-2003 | Collaborative international studies on the long term effects of Prenatal Treatment of Congenital Adrenal Hyperplasia (PREDEX)

M Ritzén, A Wedell, S Lajic, R Voutilainen, K Main, M Ginalska–Malinowska, C Brain, P Hindmarsh, L Ibañez, M Forest (Sweden, Finland, Poland, Denmark, United Kingdom, Spain, France)